Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

This study has been completed.
Boehringer Ingelheim
Information provided by (Responsible Party):
Presidio Pharmaceuticals, Inc. Identifier:
First received: May 17, 2013
Last updated: November 24, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 20, 2015